Floatz logo

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

Non-Small Cell Squamous Lung Carcinoma

Explore 53 assets in Non-Small Cell Squamous Lung Carcinoma →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07418931CT.gov
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
—Not Yet Recruiting———
NCT06463665CT.gov
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Non-Small Cell Squamous Lung Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset)Gruppo Oncologico Italiano di Ricerca ClinicaP2CCC · 53
CarboplatinGruppo Oncologico Italiano di Ricerca ClinicaP3BBB
PembrolizumabShanghai Henlius BiotechP3BB
SerplulimabShanghai Henlius BiotechP3BB
Cis-Diamminedichloroplatinum IiGruppo Oncologico Italiano di Ricerca ClinicaP3BB
DocetaxelShanghai Henlius BiotechP3BB
TislelizumabBeOne MedicinesP3BB
CatequentinibChia Tai Tianqing Pharmaceutical Group Co., Ltd.P3BB
OlaparibMerck Sharp & Dohme LLCP3BB

+42 more in the Non-Small Cell Squamous Lung Carcinoma cohort

Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

IndicationSponsorPhaseRating
Skin Squamous Cell Carcinoma—P3BB · 66
Lung Cancer—P2/3BB · 65
Nonpapillary Renal Cell Carcinoma—P2BB · 65

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Non-Small Cell Squamous Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-non-small-cell-squamous-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →